Role of gemcitabine in cancer therapy
Top Cited Papers
- 1 February 2005
- journal article
- review article
- Published by Taylor & Francis in Future Oncology
- Vol. 1 (1) , 7-17
- https://doi.org/10.1517/14796694.1.1.7
Abstract
Gemcitabine, a pyrimidine nucleoside antimetabolite, is one of the most promising new cytotoxic agents. The drug has shown activity in a variety of solid tumors, and has been approved for the treatment of non-small cell lung cancer, pancreatic, bladder, and breast cancer. Recent data showed that gemcitabine is also active against ovarian cancer. Gemcitabine has a good toxicity profile, with myelosuppression being the most common side effect, while non-hematological events are relatively uncommon. The low toxicity profile makes the drug a valid option for unfit and elderly patients. Due to the synergistic activity with other chemotherapeutic compounds, mainly cisplatinum, several trials have been conducted to evaluate the efficacy and tolerability of gemcitabine in combination with other cytotoxic agents. Current clinical trials are evaluating the role of gemcitabine in combination with new targeted therapies.Keywords
This publication has 76 references indexed in Scilit:
- Randomized Phase II Trial of Sequential Chemotherapy in Advanced Non-Small Cell Lung Cancer (SWOG 9806)Clinical Cancer Research, 2004
- Gene Expression as a Predictive Marker of Outcome in Stage IIB-IIIA-IIIB Non-Small Cell Lung Cancer After Induction Gemcitabine-Based Chemotherapy Followed By Resectional SurgeryClinical Cancer Research, 2004
- Three-Arm Randomized Study of Two Cisplatin-Based Regimens and Paclitaxel Plus Gemcitabine in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group—EORTC 08975Journal of Clinical Oncology, 2003
- Phase III trial of gemcitabine and carboplatin versus mitomycin, ifosfamide, and cisplatin or mitomycin, vinblastine, and cisplatin in patients with advanced nonsmall cell lung carcinomaCancer, 2003
- Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trialThe Lancet, 2001
- Activity and toxicity of gemcitabine and gemcitabine+vinorelbine in advanced non-small-cell lung cancer elderly patientsLung Cancer, 2001
- Gemcitabine monotherapy (GEM) versus cisplatin-based chemotherapy in symptomatic advanced NSCLC: A prospective randomised comparison of symptom controlLung Cancer, 2000
- Second- and third-line treament of metastatic breast cancer with gemcitabineEuropean Journal Of Cancer, 1998
- A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinumEuropean Journal Of Cancer, 1998
- Activity of gemcitabine in patients with non-small cell lung cancer: A multicentre, extended phase II studyEuropean Journal Of Cancer, 1996